SogoTrade Research Center








For Company Research, enter symbol or keyword and choose type of research:    Symbol Search
Johnson & Johnson
(NYSE: JNJ) Add to Portfolio
$140.98
+0.99 (+0.71%)
as of Dec 11, 2019

Last 140.98
Change +0.99 (+0.71%)
Open 140.93
Prev. Close 139.99
Today's Range
140.63 141.98
52wk Range
121.00 148.59
Volume 6,631,500
Avg Volume 6,532,135
Sector SIC-2834 Pharmaceutical Preparations

Recent Headlines
The "Monoclonal Antibodies (mAbs) Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering. (full story)
JNJ: 140.98 (+0.99), MRK: 88.98 (-0.12)
Spindletop Capital Management, a healthcare-focused growth equity firm, is pleased to announce the promotion of Kelly Huang, Ph.D. as a Managing Director of Spindletop Capital. The promotion was in recognition of Dr. Huang's role (full story)
: (), JNJ: 140.98 (+0.99), OBLN: 1.85 (+0.09)
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review fourth-quarter results. Alex Gorsky, Chairman and Chief Executive Officer; Joseph J. Wolk, Ex (full story)
JNJ: 140.98 (+0.99)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 3 CANDOR study showing that the addition of Darzalex(R) (daratumumab) to carfilzomib (Kyprolis(R)) and dexamethasone (DKd), compared (full story)
JNJ: 140.98 (+0.99)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 3 CANDOR study showing the addition of DARZALEX® (daratumumab) to carfilzomib (Kyprolis®) and dexamethasone (DKd), compared t (full story)
JNJ: 140.98 (+0.99)
 
Performance Comparison
Name Today 3-Month 1-Year
JNJ +0.71% +8.45% -3.77%
Growth Rates
YTD +9.24%
1-Year +5.26%
3-Year +20.81%
5-Year +32.63%
10-Year +117.34%
© 2019 Market data provided and hosted by Barchart Market Data Solutions. Fundamental company data provided by Morningstar and Zacks Investment Research. SEC Filings provided by Edgar Online. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.